Identification a potential therapeutic target in castrate resistance prostate cancer by using microarray

Abstract

The androgen receptor (AR) has a crucial role in the proliferation and progression of prostate cancer. anti-androgen therapy is used in the early stage of the disease and the patients respond well,howevera significant number of patients eventually will develop resistance,entering a castrate-resistant state,with very poor prognosis,which is a major clinical challenge at the moment. Enzalutamide,have shown potential in the treatment of CRPC patients,but response is just 50% and the development of resistance to these are challenging clinic. This study aims to investigate the whole genomic expression of LNCaP prostate cancer cell line model,compared to resistant to Enzalutamide model. TROP-2 demonstrates high expression in Enzalutamide resistant cells in our gene microarray,which mightsuggest TROP-2 may serve as a biomarker of resistance. The preliminary data reveal an increase in expression of TROP-2 in the LNCaP-Enz-R cell line model,compared with parental LNCaP cell,at both the protein and mRNA levels. siRNA againstTROP-2 led a decreases in a proliferation and cell cycle progression of the LNCaP-Enz-R cell line,whereas no significant difference was noticed in the parental,androgen sensitive LNCaP cell line. In addition,Knockdown of TROP-2 decrease migration of LNCaP-Enz-R cell line significantly,while no effect was observed in parental LNCaP cell